Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
Making a major move in the obesity drug market, Pfizer PFE announced on Monday that it plans to acquire biotechnology firm Metsera MTSR by the end of the year for $4.9 billion or $47.50 a share. The deal has a potential value of up to $7.3 billion when including milestone-based payments of up to $22.50 per share, ...












